Literature DB >> 19279311

Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy.

Sivan Durbin1, Giuseppe Mirabella, J Raymond Buncic, Carol A Westall.   

Abstract

PURPOSE: To determine whether visual functions are decreased in children with infantile spasms and vigabatrin-attributed retinal toxicity.
METHODS: Contrast sensitivity and grating acuity were measured by using sweep visual evoked potential (VEP) testing in 42 children with infantile spasms (mean age, 29.23 +/- 18.31 months). All children had been exposed to vigabatrin (VGB) for a minimum of 1 month. These children were divided into retinal toxicity and no toxicity groupings based on 30-Hz flicker amplitude reductions on the full-field electroretinogram. A multivariate analysis of variance (MANOVA) compared visual functions between children with and without retinal toxicity.
RESULTS: The MANOVA showed that visual function was significantly affected by VGB retinal toxicity. Further univariate analysis revealed that grating acuity was significantly reduced in children with toxicity. No differences in contrast sensitivity were found between children with toxicity and those without.
CONCLUSIONS: Reduced visual functions from VGB-attributed retinal toxicity can be detected in children with infantile spasms with the sweep VEP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19279311      PMCID: PMC3880356          DOI: 10.1167/iovs.08-3237

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  49 in total

Review 1.  Infantile spasms.

Authors:  M Wong; E Trevathan
Journal:  Pediatr Neurol       Date:  2001-02       Impact factor: 3.372

2.  Improved processing of the steady-state evoked potential.

Authors:  Y Tang; A M Norcia
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1993 Jul-Aug

3.  Severe persistent visual field constriction associated with vigabatrin.

Authors:  T Eke; J F Talbot; M C Lawden
Journal:  BMJ       Date:  1997-01-18

4.  Characteristics of a unique visual field defect attributed to vigabatrin.

Authors:  J M Wild; C Martinez; G Reinshagen; G F Harding
Journal:  Epilepsia       Date:  1999-12       Impact factor: 5.864

5.  Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer.

Authors:  John M Wild; Catherine R Robson; Adrian L Jones; Ian A Cunliffe; Philip E M Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-03       Impact factor: 4.799

6.  Symptomatic and asymptomatic visual loss in patients taking vigabatrin.

Authors:  H Daneshvar; L Racette; S G Coupland; P J Kertes; A Guberman; D Zackon
Journal:  Ophthalmology       Date:  1999-09       Impact factor: 12.079

7.  Vigabatrin and tiagabine are pharmacologically different drugs. A pre-clinical study.

Authors:  G J Sills; E Butler; G G Thompson; M J Brodie
Journal:  Seizure       Date:  1999-10       Impact factor: 3.184

8.  The retina of the newborn human infant.

Authors:  I Abramov; J Gordon; A Hendrickson; L Hainline; V Dobson; E LaBossiere
Journal:  Science       Date:  1982-07-16       Impact factor: 47.728

9.  Contrast sensitivity is reduced in children with infantile spasms.

Authors:  Giuseppe Mirabella; Sharon Morong; J Raymond Buncic; O Carter Snead; William J Logan; Shelly K Weiss; Mohamed Abdolell; Carol A Westall
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-08       Impact factor: 4.799

10.  Longitudinal changes in photopic OPs occurring with vigabatrin treatment.

Authors:  Sharon Morong; Carol A Westall; Rita Nobile; J Raymond Buncic; William J Logan; Carole M Panton; Mohamed Abdolell
Journal:  Doc Ophthalmol       Date:  2003-11       Impact factor: 2.379

View more
  10 in total

Review 1.  West Syndrome: A Review and Guide for Paediatricians.

Authors:  Renato D'Alonzo; Donato Rigante; Elisabetta Mencaroni; Susanna Esposito
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

2.  Evaluating risks for vigabatrin treatment.

Authors:  Gregory L Krauss
Journal:  Epilepsy Curr       Date:  2009 Sep-Oct       Impact factor: 7.500

3.  Electroretinographic (ERG) responses in pediatric patients using vigabatrin.

Authors:  Anne Moskowitz; Ronald M Hansen; Susan E Eklund; Anne B Fulton
Journal:  Doc Ophthalmol       Date:  2012-03-20       Impact factor: 2.379

4.  Visuocortical function in infants with a history of neonatal jaundice.

Authors:  Chuan Hou; Anthony M Norcia; Ashima Madan; William V Good
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-09-02       Impact factor: 4.799

5.  Trends and Costs Associated With the Diagnosis and Treatment of Infantile Spasms: A 10-Year Multicenter Retrospective Review.

Authors:  Mindl M Weingarten; Jon A Cokley; Brady Moffett; Shannon DiCarlo; Sunita N Misra
Journal:  J Pediatr Pharmacol Ther       Date:  2021-12-22

6.  Therapeutic effect of the mesenchymal stem cells on vigabatrin-induced retinopathy in adult male albino rat.

Authors:  Ayat Mahmoud Domouky; Walaa M Samy; Walaa A Rashad
Journal:  Anat Cell Biol       Date:  2022-06-30

7.  Contributing factors to VEP grating acuity deficit and inter-ocular acuity difference in children with cerebral visual impairment.

Authors:  Nívea Nunes Cavascan; Solange Rios Salomão; Paula Yuri Sacai; Josenilson Martins Pereira; Daniel Martins Rocha; Adriana Berezovsky
Journal:  Doc Ophthalmol       Date:  2013-12-18       Impact factor: 2.379

Review 8.  VEP estimation of visual acuity: a systematic review.

Authors:  Ruth Hamilton; Michael Bach; Sven P Heinrich; Michael B Hoffmann; J Vernon Odom; Daphne L McCulloch; Dorothy A Thompson
Journal:  Doc Ophthalmol       Date:  2020-06-02       Impact factor: 2.379

9.  Vigabatrin-induced retinal toxicity is partially mediated by signaling in rod and cone photoreceptors.

Authors:  Jin Yang; Matthew C Naumann; Yi-Ting Tsai; Joaquin Tosi; Deniz Erol; Chyuan-Sheng Lin; Richard J Davis; Stephen H Tsang
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240

10.  A New Contrast Sensitivity Test for Pediatric Patients: Feasibility and Inter-Examiner Reliability in Ocular Disorders and Cerebral Visual Impairment.

Authors:  D Luisa Mayer; Christopher Patrick Taylor; Barry S Kran
Journal:  Transl Vis Sci Technol       Date:  2020-08-20       Impact factor: 3.283

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.